Core Viewpoint - The article emphasizes the need for Chinese biopharmaceutical companies to pursue high-quality international expansion and the application of AI in the healthcare sector, highlighting the challenges and opportunities in these areas [2][4]. Group 1: High-Quality International Expansion of Biopharmaceuticals - Chinese biopharmaceutical companies have accelerated their international expansion, with China supplying 30% of the global raw material drug capacity and holding about 30% of the global new drug pipeline [5]. - By 2025, the total value of China's innovative drug licensing transactions is expected to reach $135.6 billion, surpassing the U.S. and making China the largest market for innovative drug licensing [5]. - Challenges include limitations in the current international expansion models, risks of industry chain outflow, and increased international competition, which could threaten the sustainability of domestic innovation [5][6]. - The reliance on licensing deals may lead to premature outflow of core assets and hinder the establishment of a self-sustaining commercialization system [6]. - The outflow of talent and capital poses risks to the integrity of the industry chain, as international firms increasingly attract Chinese talent and companies to establish R&D centers abroad [6]. Group 2: Recommendations for High-Quality International Expansion - Strengthening the domestic market is crucial to create a dual-circulation ecosystem for innovative drugs, enhancing payment systems, and improving the accessibility of innovative drugs [7]. - A national-level strategic safety system for pharmaceutical globalization should be established, coordinating overseas registration, global clinical trials, and intellectual property protection [8]. - The industry should build a globally competitive innovation ecosystem, including international clinical trial platforms and a database for geopolitical and compliance risks [8]. - Companies need to shift from merely selling products to building capabilities, enhancing their global R&D, registration, and commercialization systems [8]. Group 3: Application of AI in Healthcare - AI has permeated various aspects of healthcare, including clinical management, hospital operations, and drug development, but it also faces challenges such as data privacy and algorithm bias [14]. - Recommendations include establishing cross-institutional data-sharing mechanisms, enhancing algorithm transparency, and creating a regulatory framework for AI in healthcare [15][16]. - The importance of maintaining the physician's role in the decision-making process is emphasized, with AI serving as a decision support system rather than a replacement for doctors [18]. Group 4: Future Trends in AI Healthcare - The potential for AI to significantly reduce the time required for drug development and approval processes is highlighted, with expectations for AI to play a major role in the pharmaceutical industry [19].